Logo image of ATAI

ATAI LIFE SCIENCES NV (ATAI) Stock Fundamental Analysis

NASDAQ:ATAI - Nasdaq - NL0015000DX5 - Common Stock - Currency: USD

2.09  -0.46 (-18.04%)

Fundamental Rating

2

Taking everything into account, ATAI scores 2 out of 10 in our fundamental rating. ATAI was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of ATAI is average, but there are quite some concerns on its profitability. ATAI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATAI had negative earnings in the past year.
In the past year ATAI has reported a negative cash flow from operations.
ATAI had negative earnings in each of the past 5 years.
In the past 5 years ATAI always reported negative operating cash flow.
ATAI Yearly Net Income VS EBIT VS OCF VS FCFATAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -65.11%, ATAI is not doing good in the industry: 70.43% of the companies in the same industry are doing better.
ATAI has a Return On Equity (-88.25%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -65.11%
ROE -88.25%
ROIC N/A
ROA(3y)-34.71%
ROA(5y)-55.84%
ROE(3y)-39.84%
ROE(5y)-66.13%
ROIC(3y)N/A
ROIC(5y)N/A
ATAI Yearly ROA, ROE, ROICATAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

ATAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATAI Yearly Profit, Operating, Gross MarginsATAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATAI remains at a similar level compared to 1 year ago.
Compared to 1 year ago, ATAI has a worse debt to assets ratio.
ATAI Yearly Shares OutstandingATAI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
ATAI Yearly Total Debt VS Total AssetsATAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -0.89, we must say that ATAI is in the distress zone and has some risk of bankruptcy.
ATAI's Altman-Z score of -0.89 is in line compared to the rest of the industry. ATAI outperforms 50.00% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that ATAI is not too dependend on debt financing.
ATAI has a Debt to Equity ratio (0.14) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -0.89
ROIC/WACCN/A
WACC6.91%
ATAI Yearly LT Debt VS Equity VS FCFATAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

ATAI has a Current Ratio of 5.81. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.81, ATAI is in the better half of the industry, outperforming 69.35% of the companies in the same industry.
ATAI has a Quick Ratio of 5.81. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.81, ATAI is in the better half of the industry, outperforming 70.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
ATAI Yearly Current Assets VS Current LiabilitesATAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ATAI have decreased strongly by -80.00% in the last year.
ATAI shows a decrease in Revenue. In the last year, the revenue decreased by -2.65%.
EPS 1Y (TTM)-80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164%
Revenue 1Y (TTM)-2.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.02%

3.2 Future

The Earnings Per Share is expected to grow by 54.45% on average over the next years. This is a very strong growth
Based on estimates for the next years, ATAI will show a very strong growth in Revenue. The Revenue will grow by 275.61% on average per year.
EPS Next Y-189.82%
EPS Next 2Y-48.27%
EPS Next 3Y-30.23%
EPS Next 5Y54.45%
Revenue Next Year21.83%
Revenue Next 2Y-25.88%
Revenue Next 3Y-12.96%
Revenue Next 5Y275.61%

3.3 Evolution

ATAI Yearly Revenue VS EstimatesATAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ATAI Yearly EPS VS EstimatesATAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATAI Price Earnings VS Forward Price EarningsATAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATAI Per share dataATAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

ATAI's earnings are expected to decrease with -30.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.27%
EPS Next 3Y-30.23%

More info and screens

0

5. Dividend

5.1 Amount

ATAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATAI LIFE SCIENCES NV

NASDAQ:ATAI (2/13/2025, 10:50:03 AM)

2.09

-0.46 (-18.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners27.07%
Inst Owner Change-76.72%
Ins Owners3.55%
Ins Owner Change0%
Market Cap350.70M
Analysts83.33
Price Target7.14 (241.63%)
Short Float %7.65%
Short Ratio7.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-57.67%
Min EPS beat(2)-115.21%
Max EPS beat(2)-0.12%
EPS beat(4)2
Avg EPS beat(4)-19.73%
Min EPS beat(4)-115.21%
Max EPS beat(4)27.97%
EPS beat(8)5
Avg EPS beat(8)15.76%
EPS beat(12)7
Avg EPS beat(12)-2.21%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-39.66%
EPS NQ rev (1m)-3.57%
EPS NQ rev (3m)9.38%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.08%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)24.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1059.52
P/FCF N/A
P/OCF N/A
P/B 2.41
P/tB 2.41
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.11%
ROE -88.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.71%
ROA(5y)-55.84%
ROE(3y)-39.84%
ROE(5y)-66.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.49%
Cap/Sales 7.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z -0.89
F-Score2
WACC6.91%
ROIC/WACCN/A
Cap/Depr(3y)1014.98%
Cap/Depr(5y)708.99%
Cap/Sales(3y)212.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-164%
EPS Next Y-189.82%
EPS Next 2Y-48.27%
EPS Next 3Y-30.23%
EPS Next 5Y54.45%
Revenue 1Y (TTM)-2.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.02%
Revenue Next Year21.83%
Revenue Next 2Y-25.88%
Revenue Next 3Y-12.96%
Revenue Next 5Y275.61%
EBIT growth 1Y19.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.78%
EBIT Next 3Y-7.51%
EBIT Next 5Y-5.62%
FCF growth 1Y16.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.21%
OCF growth 3YN/A
OCF growth 5YN/A